Patent FR1373803A successfully refreshed from Google Patents.
US4878891A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for eradicating infectious biological contaminants in body tissues
Assignee: Baylor Research Institute
•
Filing: 1987-06-25
•
Granted: 1989-11-07
•
Expires: 2007-06-25
Abstract
Abstract A method for externally eradicating infectious pathogenic contaminants, such as enveloped viruses, bacteria, trypanosomal and malarial parasites, present in body tissues, such as blood, blood components, semen, skin, and cornea, before the treated body tisues are introduced into, or transplanted onto, the body of a human or an animal. Such method includes the steps of: (1) admixing an effective, non-toxic amount of photoactive compound, whch has a selectivity for binding to the infectious pathogenic biological contaminants present therein, with the body tissues outside the body to produce a resulting body tissues; (2) passing the resulting body tissues through an irradiating cell assembly, and (3) irradiating the resulting body tissues in the irradiating path of the cell assembly for an effective period of time with an effective level of radiation such that the radiation penetrates the resulting body tissues and eradicates the photoactive-compound-bound contaminants present in the resulting body tissues and produces a decontaminated body tissue suitable for introducing into, or transplanting onto, the body of a human or animal.
Inventors
- 👤 Millard M. Judy
- 👤 James L. Matthews
- 👤 Joseph T. Newman
- 👤 Franklin Sogandares-Bernal
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 22:32
CPC Classifications
A; A61; A61L; A61L2/00; A61L2/02; A61L2/16; A61L2103/00; A61L2103/05; A61L2103/09
Claims Analysis
Total Claims: 69
Claim 1
Independent Claim
163 words
A method for eradicating infectious pathogenic biological contaminants from body fluids outside the body prior to introduction of the decontaminated body fluids into the body of a patient, said method comprising: admixing an effective, non-toxic amount of a photoactive compound with the body fluid to produce a resulting body fluid, the photoactive compound having an affinity to be selectively bound to the contaminants; passing the resulting fluid under flow conditions through a cell assembly having a predetermined flow path; and irradiating the resulting fluid in the cell assembly as same passes through the flow path with an effective level of radiation in the region of the visible spectrum, with a wavelength range upwards of about 400 nm to about 1000 nm, for an effective period of time such that the radiation penetrates the resulting fluid and exposes the photoactive-compound-bound contaminants to the radiation so as to eradicate such contaminants while maintaining the viability of said body fluids to produce viable decontaminated body fluids.
Claim 2
Independent Claim
163 words
A method for eradicating infectious pathogenic biological contaminants from body fluids outside the body prior to introduction of the decontaminated body fluids into the body of a patient, said method comprising: admixing an effective, non-toxic amount of a photoactive compound with the body fluid to produce a resulting body fluid, the photoactive compound having an affinity to be selectively bound to the contaminants; passing the resulting fluid under flow conditions through a cell assembly having a predetermined flow path; and irradiating the resulting fluid in the cell assembly as same passes through the flow path with an effective level of radiation in the region of the visible spectrum, with a wavelength range upwards of about 400 nm to about 1000 nm, for an effective period of time such that the radiation penetrates the resulting fluid and exposes the photoactive-compound-bound contaminants to the radiation so as to eradicate such contaminants while maintaining the viability of said body fluids to produce viable decontaminated body fluids.
Claim 3
Dependent Claim
31 words
The eradicating method as recited in claim 1 further comprising the step of selecting a body fluid from the group consisting of whole blood, blood plasma, serum, and fluids from plasmapheresis.
Claim 4
Dependent Claim
19 words
The eradicating method as recited in claim 1 further comprising the step of selecting a body fluid comprising semen.
Claim 5
Dependent Claim
181 words
The eradicating method as recited in claim 1 further comprising the step of selecting a photoactive compound comprising a mixture of porphrins, at least a portion of the molecules of said porphrin mixture having the molecular formula: ##STR2## said molecules with said formula being fluorescent, photosensitizing, having the capability of selectively binding to said pathogenic biological contaminants, forming a high molecular weight aggregate with absorption peaks in the ultraviolet and visible spectra in water at approximately 365, 505, 537, 575, and 615 nanometers, absorption peaks in the infrared spectrum at approximately 3.0, 3.4, 7.1, 8.1, 9.4, 12 and 15 microns, absorption peaks in carbon-13 nuclear magnetic resonance study at approximately 9.0, 18.9, 24.7, 34.5, 62, 94.5, 130-145, 171.7 ppm and possible 118 and 127 relative to a 37.5 ppm resonance peak of dimethyl sulfoxide and additional absorption peaks in carbon-13 nuclear magnetic resonance study at approximately 27.9 ppm and 68.4 ppm relative to the resonance peak of tetramethylsilane in deuterated chloroform solvent; and at least 50 percent of the porphyrins in said mixture being of said molecule having said molecular formula.
Claim 6
Dependent Claim
30 words
The method of claim 4 wherein the amount of said mixture of porphyrins admixed with said fluids is from about 0.1 to about 50 micrograms per milliliter of body fluid.
Claim 7
Dependent Claim
29 words
The method of claim 5 wherein the amount of said mixture of porphyrins admixed with said fluids is from about 2 to 50 micrograms per milliliter of body fluid.
Claim 8
Dependent Claim
41 words
The method of claim 1 wherein the level of radiation is produced by a light source having a wavelength of from about 400 to about 1000 nm and an energy density of from about 0.1 to about 50 J/cm 2 .
Claim 9
Dependent Claim
40 words
The method of claim 7 wherein the level of radiation is produced by a light source having a wavelength of from about 600 to about 700 nm and an energy density from about 1 to about 20 J/cm 2 .
Claim 10
Dependent Claim
25 words
The eradicating method as recited in claim 1 further comprising the step of selecting body fluids which contain pathogenic biological contaminants comprising an envelope-containing virus.
Claim 11
Dependent Claim
29 words
The eradicating method as recited in claim 9 further comprising the step of selecting the envelope-containing virus from the group consisting of Herpesviridae, Poxviridae, Iridoviridae, Hepadnaviridae, orthomyxoviridae, and Paramyxoviridae.
Claim 12
Dependent Claim
28 words
The eradicating method as recited in claim 9 further comprising the step of selecting the envelope-containing virus from the group consisting of Rhabdoviridae, Bunyaviridae, Filoviridae, Nodaviridae, and Togaviridae.
Claim 13
Dependent Claim
26 words
The eradicating method as recited in claim 9 further comprising the step of selecting the envelope-containing virus from the group consisting of Flaviviridae, Retroviridae, and Arenaviridae.
Claim 14
Dependent Claim
21 words
The eradicating method as recited in claim 12 further comprising the step of selecting the Retrovirividae comprising a human immunodeficiency virus.
Claim 15
Dependent Claim
35 words
The eradicating method as recited in claim 1 further comprising the step of selecting body fluids which contain pathogenic biological contaminants comprising a bacteria selected from the group consisting of Streptococcus faecalis and Bacillus subtilis.
Claim 16
Dependent Claim
25 words
The eradicating method as recited in claim 1 further comprising the step of selecting body fluids which contain pathogenic biological contaminants comprising a malarial parasite.
Claim 17
Dependent Claim
25 words
The eradicating method as recited in claim 1 further comprising the step of selecting body fluids which contain pathogenic biological contaminants comprising a trypanosomal parasite.
Claim 18
Independent Claim
327 words
A method for externally purifying blood products to eradicate pathogenic biological contaminants selected from the group consisting of envelope-containing viruses, bacteria, malarial, and trypanosomal parasites prior to introduction of the decontaminated blood products intravenously into a patient, said method comprising: admixing an effective amount of a photoactive compound with the blood products to bind the contaminant with the photoactive compound, said photoactive compound comprising a mixture of porphyrins, at least a portion of the molecules of said porphyrin mixture having the molecular formula: ##STR3## said molecules with said formula being fluorescent, phtosensitizing, having the capability of selectively binding to said pathogenic biological contaminants, forming a high molecular weight aggregate with absorption peaks in the ultraviolet and visible spectra in water at approximately 365, 505, 537, 575, and 615 nanometers, absorption peaks in the infrared spectrum at approximately 3.0, 3.4, 6.4, 7.1, 8.1, 9.4, 12 and 15 microns, absorption peaks in carbon-13 nuclear magnetic resonance study at approximately 9.0, 18.9, 24.7, 34.5, 62, 94.5, 130-145, 171.7 ppm and possible 118 and 127 relative to a 37.5 ppm resonance peak of dimethyl sulfoxide and additional absorption peaks in carbon-13 nuclear magnetic resonance study at approximately 27.9 ppm and 68.4 ppm relative to the resonance peak of tetramethylsilane in deuterated chloroform solvent; and at least 50 percent of the porphyrins in said mixture being of said molecule having said molecular formula; passing the blood products containing the porphyrins-bound contaminants through a cell assembly having a flow path exposable to a radiation source capable of irradiating the blood products as same travels along the flow path; and irradiating the blood products with a radiation source in the region of visible spectrum, with a wavelength upwards of about 400 nm to about 1000 nm for an effective period of time to permit the radiation to penetrate through the blood products in the flow path of the cell assembly and eradicate the contaminants while maintaining the viability of components in said blood products.
Claim 19
Independent Claim
327 words
A method for externally purifying blood products to eradicate pathogenic biological contaminants selected from the group consisting of envelope-containing viruses, bacteria, malarial, and trypanosomal parasites prior to introduction of the decontaminated blood products intravenously into a patient, said method comprising: admixing an effective amount of a photoactive compound with the blood products to bind the contaminant with the photoactive compound, said photoactive compound comprising a mixture of porphyrins, at least a portion of the molecules of said porphyrin mixture having the molecular formula: ##STR3## said molecules with said formula being fluorescent, phtosensitizing, having the capability of selectively binding to said pathogenic biological contaminants, forming a high molecular weight aggregate with absorption peaks in the ultraviolet and visible spectra in water at approximately 365, 505, 537, 575, and 615 nanometers, absorption peaks in the infrared spectrum at approximately 3.0, 3.4, 6.4, 7.1, 8.1, 9.4, 12 and 15 microns, absorption peaks in carbon-13 nuclear magnetic resonance study at approximately 9.0, 18.9, 24.7, 34.5, 62, 94.5, 130-145, 171.7 ppm and possible 118 and 127 relative to a 37.5 ppm resonance peak of dimethyl sulfoxide and additional absorption peaks in carbon-13 nuclear magnetic resonance study at approximately 27.9 ppm and 68.4 ppm relative to the resonance peak of tetramethylsilane in deuterated chloroform solvent; and at least 50 percent of the porphyrins in said mixture being of said molecule having said molecular formula; passing the blood products containing the porphyrins-bound contaminants through a cell assembly having a flow path exposable to a radiation source capable of irradiating the blood products as same travels along the flow path; and irradiating the blood products with a radiation source in the region of visible spectrum, with a wavelength upwards of about 400 nm to about 1000 nm for an effective period of time to permit the radiation to penetrate through the blood products in the flow path of the cell assembly and eradicate the contaminants while maintaining the viability of components in said blood products.
Claim 20
Dependent Claim
31 words
The method of claim 17 wherein the amount of said mixture of porphyrins admixed with said blood products is from about 0.1 to about 50 micrograms per milliliter of blood products.
Claim 21
Dependent Claim
31 words
The method of claim 18 wherein the amount of said mixture of porphyrins admixed with said blood products is from about 2 to about 50 micrograms per milliliter of blood products.
Claim 22
Dependent Claim
41 words
The method of claim 17 wherein the level of radiation is produced by a light source having a wavelength of from about 400 to about 700 nm and an energy density of from about 0.1 to about 50 J/cm 2 .
Claim 23
Dependent Claim
41 words
The method of claim 20 wherein the level of radiation is produced by a light source having a wavelength of from about 600 to about 700 nm and an energy density of from about 1 to about 20 J/cm 2 .
Claim 24
Dependent Claim
25 words
The eradication method as recited in claim 17 further comprising the step of selecting blood products which contain pathogenic biological contaminants comprising an envelope-containing virus.
Claim 25
Dependent Claim
29 words
The eradicating method as recited in claim 22 further comprising the step of selecting the envelope-containing virus from the group consisting of Herpesviridae, Poxviridae, Iridoviridae, Hepadnaviridae, Orthomyxoviridae, and Paramyxoviridae.
Claim 26
Dependent Claim
28 words
The eradicating method as recited in claim 22 further comprising the step of selecting the envelope-containing virus from the group consisting of Rhabdoviridae, Bunyaviridae, Filoviridae, Nodaviridae, and Togaviridae.
Claim 27
Dependent Claim
26 words
The eradication method as recited in claim 22 further comprising the step of selecting the envelope-containing virus from the group consisting of Flaviviridae, Retroviridae, and Arenaviridae.
Claim 28
Dependent Claim
21 words
The eradicating method as recited in claim 25 further comprising the step of selecting the Retroviridae comprising a human immunodeficiency virus.
Claim 29
Dependent Claim
35 words
The eradicating method as recited in claim 17 further®r comprising the step of selecting blood products which contain pathogenic biological contaminants comprising a bacteria selected from the group consisting of Streptococcus faecalis and Bacillus subtilis.
Claim 30
Dependent Claim
25 words
The eradicating method as recited in claim 17 further comprising the step of selecting body fluids which contain pathogenic biological contaminants comprising a malarial parasite.
Claim 31
Dependent Claim
25 words
The eradicating method as recited in claim 17 further comprising the step of selecting blood products which contain pathogenic biological contaminants comprising a trypanosomal parasite.
Claim 32
Independent Claim
167 words
A method for eradicating infectious pathogenic biological contaminants from body tissues outside the body prior to transplanting the decontaminated body tissues onto the body of the patient, said method comprising: removing by excision from a donor a piece of human tissue that is translucent to light; admixing a effective, non-toxic amount of a photoactive compound with the body tissue suspended in a physiologically acceptabIe saline solution, the photoactive compound having an affinity to be selectively bound to the contaminants; and irradiating the resulting suspension of the body tissue gently a(g)gitated in a physiologically acceptable saline solution with an effective level of radiation in the region of the visible spectrum, with a wavelength range upwards of about 400 nm to about 1000 nm, for an effective period of time such that the radiation penetrates the body tissue and exposes the photoactive-compound-bound contaminants to the radiation so as to eradicate such contaminants while maintaining the viability of said body tissue to produce viable decontaminated body tissues suitable for transplantation.
Claim 33
Independent Claim
167 words
A method for eradicating infectious pathogenic biological contaminants from body tissues outside the body prior to transplanting the decontaminated body tissues onto the body of the patient, said method comprising: removing by excision from a donor a piece of human tissue that is translucent to light; admixing a effective, non-toxic amount of a photoactive compound with the body tissue suspended in a physiologically acceptabIe saline solution, the photoactive compound having an affinity to be selectively bound to the contaminants; and irradiating the resulting suspension of the body tissue gently a(g)gitated in a physiologically acceptable saline solution with an effective level of radiation in the region of the visible spectrum, with a wavelength range upwards of about 400 nm to about 1000 nm, for an effective period of time such that the radiation penetrates the body tissue and exposes the photoactive-compound-bound contaminants to the radiation so as to eradicate such contaminants while maintaining the viability of said body tissue to produce viable decontaminated body tissues suitable for transplantation.
Claim 34
Dependent Claim
25 words
The eradicating method as recited in claim 30 further comprising the step of selecting a body tissue from the group consisting of skin and cornea.
Claim 35
Dependent Claim
182 words
The eradicating method as recited in claim 30 further comprising the step of selecting a photoactive compound comprising a mixture of porphyrins, at least a portion of the molecules of said porphyrin mixture having the molecular formula: ##STR4## said molecules with said formula being fluorescent, photosensitizing, having the capability of selectively binding to said pathogenic biological contaminants, forming a high molecular weight aggregate with absorption peaks in the ultraviolet and visible spectra in water at approximately 365, 505, 537, 575, and 615 nanometers, absorption peaks in the infrared spectrum at approximately 3.0, 3.4, 6.4, 7.1, 8.1, 9.4, 12 and 15 microns, absorption peaks in carbon-13 nuclear magnetic resonance study at approximately 9.0, 18.9, 24.7, 34.5, 62, 94.5, 130-145, 171.7 ppm and possible 118 and 127 relative to a 37.5 ppm resonance peak of dimethyl sulfoxide and additional absorption peaks in carbon-13 nuclear magnetic resonance study at approximately 27.9 ppm and 68.4 ppm relative to the resonance peak of tetramethylsilane in deuterated chloroform solvent; and at least 50 percent of the porphyrins in said mixture being of said molecule having said molecular formula.
Claim 36
Dependent Claim
41 words
The method of claim 30 wherein the level of radiation is produced by a light source having a wavelength of from about 400 to about 700 nm and an energy density of from about 0.1 to about 20 J/cm 2 .
Claim 37
Dependent Claim
40 words
The method of claim 33 wherein the level of radiation is produced by a light source having a wavelength of from about 600 to about 700 nm and an energy density from about 1 to about 20 J/cm 2 .
Claim 38
Dependent Claim
25 words
The eradicating method as recited in claim 30 further comprising the step of selecting body tissues which contain pathogenic biological contaminants comprising an envelope-containing virus.
Claim 39
Dependent Claim
29 words
The eradicating method as recited in claim 35 further comprising the step of selecting the envelope-containing virus from the group consisting of Herpesviridae, Poxviridae, Iridoviridae, Hepadnaviridae, Orthomyxoviridae, and Paramyxoviridae.
Claim 40
Dependent Claim
28 words
The eradicating method as recited in claim 35 further comprising the step of selecting the envelope-containing virus from the group consisting of Rhabdovirdae, Bunyaviridae, Filoviridae, Nodaviridae, and Togaviridae.
Claim 41
Dependent Claim
26 words
The eradicating method as recited in claim 35 further comprising the step of selecting the envelope-containing virus from the group consisting of Flaviviridae, Retroviridae, and Arenaviridae.
Claim 42
Dependent Claim
21 words
The eradicating method as recited in claim 38 further comprising the step of selecting the Retroviridae comprising a human immunodeficiency virus.
Claim 43
Dependent Claim
35 words
The eradicating method as recited in claim 30 further comprising the step of selecting body tissues which contain pathogenic biological contaminants comprising a bacteria selected from the group consisting of Streptococcus faecalis and Bacillus subtilis.
Claim 44
Dependent Claim
25 words
The eradicating method as recited in claim 30 further comprising the step of selecting body tissues which contain pathogenic biological contaminants comprising a malarial parasite.
Claim 45
Dependent Claim
25 words
The eradicating method as recited in claim 30 further comprising the step of selecting body tissues which contain pathogenic biological contaminants comprising a trypanosomal parasite.
Claim 46
Independent Claim
175 words
A method for extracorporeal treatment of the blood of a patient infected with infectious pathogenic biological contaminants said method comprising: removing blood from the body of a patient infected with infectious pathogenic biological contaminants; adding to said blood, before the removal of the blood, an effective, non-toxic amount of photoactive compound having an affinity to be selectively bound to the infectious contaminants; passing said treated blood through a cell assembly having a predetermined flow path; irradiating said contaminated blood admixed with photoactive compound in the cell assembly as same passes through the flow path with an effective level of radiation in the region of visible spectrum, with a wavelength range upwards of about 400 nm to about 1000 nm, for an effective period of time such that the radiation penetrates the blood and exposes the photoactive-compound-bound infectious contaminants to the radiation so as to eradicate such infectious contaminants while maintaining the viability of components in said blood to produce a viable and decontaminated blood; and returning said viable and decontaminated blood to the patient's body.
Claim 47
Independent Claim
175 words
A method for extracorporeal treatment of the blood of a patient infected with infectious pathogenic biological contaminants said method comprising: removing blood from the body of a patient infected with infectious pathogenic biological contaminants; adding to said blood, before the removal of the blood, an effective, non-toxic amount of photoactive compound having an affinity to be selectively bound to the infectious contaminants; passing said treated blood through a cell assembly having a predetermined flow path; irradiating said contaminated blood admixed with photoactive compound in the cell assembly as same passes through the flow path with an effective level of radiation in the region of visible spectrum, with a wavelength range upwards of about 400 nm to about 1000 nm, for an effective period of time such that the radiation penetrates the blood and exposes the photoactive-compound-bound infectious contaminants to the radiation so as to eradicate such infectious contaminants while maintaining the viability of components in said blood to produce a viable and decontaminated blood; and returning said viable and decontaminated blood to the patient's body.
Claim 48
Dependent Claim
181 words
The eradicating method as recited in claim 43 further comprising the step of selecting a photoactive compound comprising a mixture of porphyrins, at least a portion of the molecules of said porphyrin mixture having the molecular formula: ##STR5## said molecules with said formula being fluorescent, photosensitizing, having the capability of selectively binding to said pathogenicbiological contaminants, forming a high molecular weight aggregate with absorption peaks in the ultraviolet and visible spectra in water at approximately 365, 505, 537, 575, and 615 nanometers, absorption peaks in the infrared spectrum at approximately 3.0, 3.4, 6.4, 7.1, 8.1, 9.4, 12 and 15 microns, absorption peaks in carbon-13 nuclear magnetic resonance study at approximately 9.0, 18.9, 24.7, 34.5, 62, 94.5, 130-145, 171.7 ppm and possible 118 and 127 relative to a 37.5 ppm resonance peak of dimethyl sulfoxide and additional absorption peaks in carbon-13 nuclear magnetic resonance study at approximately 27.9 ppm and 68.4 ppm relative to the resonance peak of tetramethylsilane in deuterated chloroform solvent; and at least 50 percent of the porphyrins in said mixture being of said molecule having said molecular formula.
Claim 49
Dependent Claim
34 words
The eradicating method as recited in claim 44 further comprising the step of administering said mixture of porphyrins to the patient prior to the removal of the blood from the patient's body for irradiation.
Claim 50
Dependent Claim
39 words
The eradicating method as recited in claim 45 further comprising the step of administering said mixture of porphyrins to the patient between about one hour and about one week prior to the removal of the patient's blood for irradiation.
Claim 51
Dependent Claim
37 words
The eradicating method as recited in claim 45 further comprising the step of administering said mixture of porphyrins at a dosage from about 0.5 mg to about 40 mg per kg of body weight of the patient.
Claim 52
Dependent Claim
38 words
The eradicating method as recited in claim 44 further comprising the step of admixing said mixture of porphyrins, dissolved in a physiologically acceptable saline solution, with the blood after said blood has been removed from the patient's body.
Claim 53
Dependent Claim
36 words
The eradicating method as recited in claim 48 further comprising the step of admixing said mixture of porphyrins with said blood in an amount from about 0.1 to about 50 micrograms per milliliter of said blood.
Claim 54
Dependent Claim
36 words
The eradicating method as recited in claim 49 further comprising the step of admixing said mixture of porphyrins with said blood in an amount from about 2 to about 50 micrograms per milliliter of said blood.
Claim 55
Dependent Claim
41 words
The method of claim 43 wherein the level of radiation is produced by a light source having a wavelength of from about 600 to about 1000 nm and an energy density of from about 1 to about 50 J/cm 2 .
Claim 56
Dependent Claim
41 words
The method of claim 51 wherein the level of radiation is produced by a light source having a wavelength of from about 600 to about 700 nm and an energy density of from about 1 to about 20 J/cm 2 .
Claim 57
Dependent Claim
25 words
The eradicating method as recited in claim 43 further comprising the step of selecting a blood which contains pathogenic biological contaminants comprising an envelope-containing virus.
Claim 58
Dependent Claim
29 words
The eradicating method as recited in claim 53 further comprising the step of selecting the envelope-containing virus from the group consisting of Herpesviridae, Poxviridae, Iridoviridae, Hepadnaviriae, Orthomyxoviridae, and Paramyxoviridae.
Claim 59
Dependent Claim
28 words
The eradicating method as recited in claim 53 further comprising the step of selecting the envelope-containing virus from the group consisting of Rhabdoviridae, Bunyaviridae, Filoviridae, Nodaviridae, and Togaviridae.
Claim 60
Dependent Claim
26 words
The eradicating method as recited in claim 53 further comprising the step of selecting the envelope-containing virus from the group consisting of Flaviviridae, Retroviridae, and Arenaviridae.
Claim 61
Dependent Claim
21 words
The eradicating method as recited in claim 56 further comprising the step of selecting the Retroviridae comprising a human immunodeficiency virus.
Claim 62
Dependent Claim
35 words
The eradicating method as recited in cIaim 43 further comprising the step of selecting a blood which contains pathogenic biological contaminants comprising a bacteria selected from the group consisting of Streptococcus faecalis and Bacillus subtilis.
Claim 63
Dependent Claim
35 words
The eradicating method as recited in cIaim 43 further comprising the step of selecting a blood which contains pathogenic biological contaminants comprising a bacteria selected from the group consisting of Streptococcus faecalis and Bacillus subtilis.
Claim 64
Dependent Claim
22 words
The eradicating method as recited in claim 43 further comprising the step of selecting the pathogenic biological contaminants comprising a malarial parasite.
Claim 65
Dependent Claim
25 words
The eradicating method as recited in claim 43 further comprising the step of selecting a blood which contains pathogenic biological contaminants comprising a trypanosomal parasite.
Claim 66
Independent Claim
177 words
A method for extracorporeal treatment of the blood of a patient infected with infectious pathogenic biological contaminants said method comprising: removing blood from the body of a patient infected with infectious pathogenic foreign biological contaminants; adding to said blood, after the removal of the blood, an effective, non-toxic amount of photoactive compound having an affinity to be selectively bound to the infectious contaminants; passing said treated blood through a cell assembly having a pedetermined flow path; irradiating said contaminated blood admixed with photoactive compound in the cell assembly as the same passes through the flow path with an effective level of radiation in the region of visible spectrum, with a wavelength range upwards of about 400 nm to about 1000 nm, for an effective period of time such that the radiation penetrates the blood and exposes the photoactive-compound-bound infectious contaminants to the radiation so as to eradicate such infectious contaminants while maintaining the viability of compounds in said blood to produce a viable and decontaminated blood; and returning said viable and decontaminated blood to the patient's body.
Claim 67
Independent Claim
177 words
A method for extracorporeal treatment of the blood of a patient infected with infectious pathogenic biological contaminants said method comprising: removing blood from the body of a patient infected with infectious pathogenic foreign biological contaminants; adding to said blood, after the removal of the blood, an effective, non-toxic amount of photoactive compound having an affinity to be selectively bound to the infectious contaminants; passing said treated blood through a cell assembly having a pedetermined flow path; irradiating said contaminated blood admixed with photoactive compound in the cell assembly as the same passes through the flow path with an effective level of radiation in the region of visible spectrum, with a wavelength range upwards of about 400 nm to about 1000 nm, for an effective period of time such that the radiation penetrates the blood and exposes the photoactive-compound-bound infectious contaminants to the radiation so as to eradicate such infectious contaminants while maintaining the viability of compounds in said blood to produce a viable and decontaminated blood; and returning said viable and decontaminated blood to the patient's body.
Claim 68
Dependent Claim
43 words
The eradicating method as recited in claim 32 and further comprising the step of admixing said mixture of porphyrins, from about 0.1 to about 50 micrograms per milligram of body tissue, in a physiologically acceptable saline solution with said suspension of body tissue.
Claim 69
Dependent Claim
42 words
The eradicating method as recited in claim 62 and further comprising the step of admixing said mixture of porphyrins, from about 2 to 50 micrograms per milligram of body tissue, in a physiologically acceptable saline solution with said suspension of body tissue.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-11-06 | 1993-05-08 | 1993-11-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-11-06 | 1997-05-08 | 1997-11-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-11-06 | 2001-05-08 | 2001-11-07 | $7700.00 | Window Closed / Lapsed |